Navigation Links
Onyx Pharmaceuticals Names John E. Osborn Senior Vice President, Global Corporate Affairs
Date:7/9/2012

SOUTH SAN FRANCISCO, Calif., July 9, 2012 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. (NASDAQ:   ONXX) today announced that it has appointed John E. Osborn as Senior Vice President, Global Corporate Affairs.  In his role, Mr. Osborn will report to N. Anthony Coles, M.D., President and Chief Executive Officer, and will be responsible for the public and government affairs activities of the company, as well as key stakeholder relationships.

"As a lawyer, policy advocate and former diplomat, John brings a diverse and extensive background to Onyx, with broad experience across the life sciences industry and the U.S. government," said Dr. Coles.  "John is a proven leader and his unique expertise aligns well with our plan for global growth as a multi-product company reaching patients around the world."

Prior to joining Onyx, Mr. Osborn was Executive Vice President, General Counsel and Secretary at Dendreon Corporation.  Previously, he held similar roles at US Oncology, Inc., where he worked on its merger with McKesson, and at Cephalon, Inc., where he managed legal, public and government affairs during a critical growth period.  Mr. Osborn also served with the U.S. Department of State during the George H.W. Bush administration, and in 2008 was confirmed by the Senate as a member of the bipartisan United States Advisory Commission on Public Diplomacy.  He has held faculty appointments at Oxford, Princeton and the University of Washington, served on the board of governors of the East-West Center in Hawaii, and examined the peace process in Northern Ireland as an Eisenhower Fellow.  Early in his career he clerked for Judge Albert V. Bryan of the U.S. Court of Appeals for the Fourth Circuit, and practiced corporate law in Boston for Hale and Dorr (now WilmerHale).  Mr. Osborn received his undergraduate degree in economics and history from the University of Iowa, his law degree from the University of Virginia School of Law, and his master's degree in international public policy from The Johns Hopkins University School of Advanced International Studies.

About Onyx Pharmaceuticals, Inc.

Based in South San Francisco, California, Onyx Pharmaceuticals, Inc. is a global biopharmaceutical company engaged in the development and commercialization of innovative therapies for improving the lives of people with cancer.  The company is focused on developing novel medicines that target key molecular pathways.  For more information about Onyx, visit the company's website at www.onyx.com.

Forward-Looking Statements

This news release contains "forward-looking statements" of Onyx within the meaning of the federal securities laws.  These forward-looking statements include without limitation, statements regarding the progress and results of preclinical and clinical development of carfilzomib.  These statements are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including risks related to the development and commercialization of pharmaceutical products.  Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements.  Reference should be made to Onyx's Annual Report on Form 10-K for the year ended December 31, 2011, filed with the Securities and Exchange Commission under the heading "Risk Factors" and Onyx's Quarterly Reports on Form 10-Q for a more detailed description of such factors.  Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date of this release.  Onyx undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date of this release except as required by law.


'/>"/>
SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Inovio Pharmaceuticals to Present at JMP Investor Conference
2. Inspiration Biopharmaceuticals Reports Positive Interim Results from the Accur8 Phase 2/3 Study of OBI-1 in Acquired Hemophilia A at WFH 2012 World Congress
3. Vanda Pharmaceuticals to Present at the JMP Securities Healthcare Conference
4. Amgen Completes Acquisition of KAI Pharmaceuticals
5. Optimer Pharmaceuticals to Present at the 7th Annual JMP Securities Healthcare Conference
6. Arena Pharmaceuticals Promotes Craig M. Audet to Executive Officer as Senior Vice President, Operations and Head of Global Regulatory Affairs
7. Isis Pharmaceuticals to Present at the 7th Annual JMP Securities Healthcare Conference
8. Law Office of Brodsky & Smith, LLC Announces Investigation of Amylin Pharmaceuticals, Inc.
9. The Leukemia & Lymphoma Society and Celator Pharmaceuticals Announce $5 Million Partnership to Support Phase 3 Development of CPX-351 for AML
10. Amylin Pharmaceuticals, Inc. Shareholder Alert: Bernstein Liebhard LLP Announces Investigation Of Acquisition By Bristol-Myers Squibb Company
11. Nouveau Life Pharmaceuticals (NOUV) In Talks with International Mass Distribution Firms
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Any dentist who has made an implant supported ... Many of them do not even offer this as a ... laboratory costs involved. And those who ARE able to offer ... high cost that the majority of today,s patients would not ... Zadeh , founder of Dental Evolutions Inc. and inventor of ...
(Date:6/23/2016)... , June 23, 2016  In a startling report released today, ... their residents by lacking a comprehensive, proven plan to eliminate prescription ... definitive ranking of how states are tackling the worst drug crisis ... four states – Kentucky , New ... Vermont . Of the 28 failing states, three – ...
(Date:6/23/2016)... Research and Markets has announced the ... 2016 - Forecast to 2022" report to their offering. ... up to date financial data derived from varied research sources ... with potential impact on the market during the next five ... comprises of sub markets, regional and country level analysis. The ...
Breaking Medicine Technology:
(Date:6/25/2016)... Montreal, Canada (PRWEB) , ... June 25, 2016 , ... ... the pursuit of success. In terms of the latter, setting the bar too high ... low, risk more than just slow progress toward their goal. , Research from ...
(Date:6/24/2016)... ... 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was out of ... verbally and physically. , “When something upset him, he couldn’t control his emotions,” remembers Marcy. ... throw rocks at my other children and say he was going to kill them. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA is ... Road To Recovery® program to drive cancer patients to and from their cancer treatments. ... the highest quality of life and ongoing independence. Getting to and from medical ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Haute ... Dr. Barry M. Weintraub as a prominent plastic surgeon and the network’s newest ... world, and the most handsome men, look naturally attractive. Plastic surgery should be ...
(Date:6/24/2016)... ... ... Venture Construction Group (VCG) sponsors Luke’s Wings 5th ... Woodmont Country Club at 1201 Rockville Pike, Rockville, Maryland, 20852. The event raised ... have been wounded in battle and their families. Venture Construction Group is a 2016 ...
Breaking Medicine News(10 mins):